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Abstract
Background: The serious mental illness Health Improvement Profile [HIP] is a brief pragmatic tool, which enables
mental health nurses to work together with patients to screen physical health and take evidence-based action
when variables are identified to be at risk. Piloting has demonstrated clinical utility and acceptability.
Methods/Design: A single blind parallel group cluster randomised controlled trial with secondary economic
analysis and process observation. Unit of randomisation: mental health nurses [MHNs] working in adult community
mental health teams across two NHS Trusts. Subjects: Patients over 18 years with a diagnosis of schizophrenia,
schizoaffective or bipolar disorder on the caseload of participating MHNs. Primary objective: To determine the
effects of the HIP programme on patients’ physical wellbeing assessed by the physical component score of the
Medical Outcome Study (MOS) 36 Item Short Form Health Survey version 2 [SF-36v2]. Secondary objectives: To
determine the effects of the HIP programme on: cost effectiveness, mental wellbeing, cardiovascular risk, physical
health care attitudes and knowledge of MHNs and to determine the acceptability of the HIP Programme in the
NHS. Consented nurses (and patients) will be randomised to receive the HIP Programme or treatment as usual.
Outcomes will be measured at baseline and 12 months with a process observation after 12 months to include
evaluation of patients’ and professionals’ experience and observation of any effect on care plans and primary-
secondary care interface communication. Outcomes will be analysed on an intention-to-treat (ITT) basis.
Discussion: The results of the trial and process observation will provide information about the effectiveness of the
HIP Programme in supporting MHNs to address physical comorbidity in serious mental illness. Given the current
unacceptable prevalence of physical comorbidity and mortality in the serious mental illness population, it is hoped
the HIP trial will provide a timely contribution to evidence on organisation and delivery of care for patients,
clinicians and policy makers.
Trial Registration: ISRCTN: ISRCTN41137900
Background
Serious mental illness and physical comorbidity
Improving the physical health of people with serious
mental illness [SMI] (people with a diagnosis of schizo-
phrenia, schizoaffective or bipolar disorder) is an impor-
tant public health challenge [1,2]. Comorbid physical
illness dramatically reduces life expectancy; epidemiolo-
gical studies report 20-25 years earlier mortality in schi-
zophrenia and 10-15 years in bipolar disorder [3,4].
Metabolic disorders such as diabetes, hyperlipidemia
and hypertension are highly prevalent, exceeding 50% in
some studies [5]. Cardiovascular disease [CVD] is the
most common cause of early mortality; lifestyle and risk
factors are common and may be exacerbated by antipsy-
chotic medication [6,7]. Rates of respiratory disease,
HIV and some cancers are higher than expected [8].
Poor eye, foot, bowel and dental health, sleep problems
and sexual dissatisfaction contribute to social exclusion
[9-11].
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The physical health needs of SMI patients has long been
overlooked by both primary and secondary care [12-14]
prompting a number of guidelines (e.g. [15-18]. The
first step is monitoring but randomised controlled trial
evidence to support a robust method in this population
is lacking [19].
Although considerably more likely than the general
population to visit their GP, 2% SMI patients had had
their cholesterol checked and recorded in one study
[20]. In 606 inpatients, 18% had their weight recorded
and 4% their cholesterol checked during admission [21].
Data from 1,966 outpatients revealed 11% had docu-
mented results for the four tests that should be underta-
ken each year for those at risk of metabolic syndrome
[22]. No formal provision to record, share and use infor-
mation from physical health screening in the Care Pro-
gramme Approach has been reported by 28% of Local
Implementation Teams [23]. The Department of Health
[DH] has encouraged primary and secondary services to
work together to improve physical health outcomes and
adopt local care pathways, recommending a physical
health ‘wellbeing programme’ [WBP] [1]. The WBP,
facilitated by nurse advisors trained by key opinion lea-
ders and funded by the pharmaceutical industry, enabled
some NHS Trusts to set up physical health clinics at
pilot sites, almost exclusively focusing on identifying
and reducing modifiable cardiovascular risk factors.
Wider dissemination of thep r o g r a m m ew a sb yac a s -
cade of training from the nurse advisors who were then
withdrawn. Data from one large mental health [MH]
Trust indicate that this approach diluted fidelity to the
original WBP model with fewer sessions offered to
patients and no replication of the positive results seen
[24].
Mental Health Nurses [MHNs] are well placed to pro-
file SMI patients’ physical health needs, plan and facili-
tate evidence based care and communicate with primary
care colleagues [8] but there is poor preparation for this
role [25] with half reporting no previous training in one
survey [26]. Relatively short courses can be effective in
enabling MHNs to acquire competence and confidence
in new ways of working that improve clinical outcomes
[27,28]. Two small studies have shown the potential to
improve MHNs’ detection of physical health problems
following brief training [29,30].
The serious mental illness Health Improvement Profile
[HIP]
The HIP is a 27-item gender specific profiling tool that
enables MHNs and patients to work together to iden-
tify and ‘red flag’ aspects of physical health. Impor-
tantly the HIP is a change tool, not merely a detection
tool. It directs the nurse and patient to select the
action to take next and provides a template for com-
municating with psychiatrists and general practitioners
[GPs]. The HIP has been designed to fit on one side of
A4 paper and has 5 columns indicating the variable at
risk for assessment (e.g. smoking status), level (result),
Green (e.g. ‘non smoker’), Red (e.g. ‘passive smoker/
smoker’) and the recommended action for red group
(e.g. advice that all smoking is associated with health
risks, refer to NHS smoking cessation service). The
HIP should be completed at least annually, the recom-
mended frequency of screening for patients with SMI
[17,18].
A series of literature reviews established the variables at
risk in SMI, normal and abnormal ranges and recom-
mended action informing the development of the HIP
through piloting stages [8,31]. Utility and acceptability
was demonstrated by evaluation of an exploratory case
series where patients made lifestyle changes as a result of
completing the HIP with their nurse and GPs and psy-
chiatrists altered treatment plans [32]. Training to facili-
tate the HIP takes between 3 and 6 hours. The 6-hour
training package includes how to use the HIP, how to
engage patients in health behaviour change and support
to develop a patient specific health action plan. A HIP
manual is provided. It is unknown if the HIP Programme
is more effective in improving physical wellbeing in
patients with SMI after a year than current practice in
this population so a randomised controlled trial has been
recommended [19].
Methods/design
The study is aimed at people living with SMI in the
community (defined as those with a diagnosis of schizo-
phrenia, schizoaffective or bipolar disorder) and will
investigate the impact of the HIP and the brief HIP
training package for nurses [HIP Programme] in
patients with SMI on the caseload of community Mental
Health Nurses [MHNs]. Registered MHNs working in a
community mental health setting will be recruited from
adult community mental health, assertive outreach and
recovery teams serving the urban, coastal and rural
communities of Norfolk, North Suffolk and Lincoln-
shire. Once the MHN enters the trial, eligible SMI
patients will be identified from their caseload and
invited to participate. A cluster randomised controlled
design with the nurse as the unit of randomisation has
been selected because our aim is to improve patient out-
comes by an intervention directed at the level of the
nurse (the HIP Programme). We have planned the study
in accordance with the Consolidated Standards of
Reporting Trials [CONSORT] cluster trial reporting
extension standards [33].
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The primary objective is to determine the effects of the
HIP programme on patients’ physical wellbeing over 12
months compared to treatment as usual (objective 1).
The burden of physical comorbidity in patients with
SMI is likely to incur additional service costs in terms
of diagnostic screening and treatment of previously
unrecognised or untreated comorbidity. An economic
evaluation will assess if the HIP Programme represents
a cost-effective use of scarce NHS resources (objective
2). Impact of the HIP Programme on mental health
related quality of life (objective 3) and the physical
health care attitudes and knowledge of MHN (objective
4) will be evaluated. In addition to the main trial, any
modification of cardiovascular risk factors by patients
(objective 5) and evidence of acceptability of the HIP
Programme to the NHS (objective 6) will be explored in
the HIP Programme group. There will, therefore, be two
parts to the study:
Part 1
Impact and cost effectiveness (Objectives 1-3)
A 2-arm single-blind, parallel group randomised con-
trolled trial design (clustered at the level of the MHN).
MHNs will be randomised to either the HIP Programme
group or treatment as usual [TAU]. Figure 1 sum-
marises the trial design. For details of inclusion and
exclusion criteria of MHNs please see pages 12-13.
Physical health care attitude and knowledge of MHNs
(Objective 4)
MHNs attitude towards and knowledge for a physical
health care role will be measured at baseline and at 52
weeks in both groups using an online survey.
Cardiovascular risk (Objective 5)
Cardiovascular risk factors will be measured using a
‘within treatment’ g r o u pd e s i g ni nt h eH I PP r o g r a m m e
group patients at baseline and at 52 weeks to allow
before-after change to be estimated (Objective 5).
Part 2
Acceptability of the HIP Programme in the NHS (Objective 6)
To assess acceptability of the HIP Programme in the
NHS (objective 6), a process observation will be con-
ducted in the HIP Programme group. A retrospective
documentation audit of the secondary care patient
record will capture details of recorded physical health
needs, care plan interventions, goals, review dates and
any communication across the primary-secondary care
interface. Perceptions in a sample of MHNs, patients,
their psychiatrists and GPs will be explored and ana-
lysed using a semi structured interview or focus group
design.
Outcome measures
Part 1: Cluster RCT (Objectives 1-5)
The Medical Outcome Study (MOS) 36 Item Short
Form Health Survey version 2 [SF-36v2] is a self-report
multidimensional measure of health-related quality of
life and wellbeing with well established psychometric
properties [34]. The revised version of the SF36 has
improvements in item wording and format and a 6 fold
increase in the range of scores produced. Participant
burden is not increased [35]. The scales of the SF-36v2
address eight health domains and two summary mea-
sures are provided: a physical component summary
score [PCS)], and a mental component summary score
[MCS]. The PCS was selected as the primary quality of
life (QoL) outcome measure as it has been shown to
have good sensitivity to change in a population of out-
patients with schizophrenia [36]We acknowledge that, at
least theoretically, mental health-related quality of life
may change as a result of implementing the HIP
because patients will become aware of previously
unknown morbidity so the MCS will also be used.
In line with a previous economic evaluation for patients
with schizophrenia [37], levels of health care resource use
[HRU] will be captured via an amended version of the
Client Services Receipt Inventory [38]. This patient self-
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Figure 1 Summary of trial design for the HIP Cluster RCT.
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Page 3 of 11report measure (HRU (Patient)) will monitor health pro-
fessional visits, hospital admissions, medication, etc. and
be administered to all study participants at baseline and
at the 52 weeks post randomisation point. Additionally,
nurses will be asked to report the time taken to complete
the HIP, referrals made, medication changes etc. every
time the HIP is used (HRU (Nurse)).
The EuroQol 5 Dimension questionnaire [EQ-5D] is
an established, standardised health-related quality of life
instrument used extensively in clinical studies [39]. It
provides a simple descriptive profile of each respondent
and a single index value for their perceived current
health status. It comprises five items covering the
domains of mobility, self-care, usual activity, pain/dis-
comfort and anxiety/depression and a visual analogue
scale. The EQ-5D is cognitively simple, taking only a
few minutes to complete. Instructions to respondents
are included in the questionnaire. It will be administered
to all patient participants in the study at baseline and at
the 52 weeks post randomisation visit.
The Mental Health Nurse Physical Health Attitude
Scale [PHASe] is a 29 item questionnaire with estab-
lished validity, designed to capture MHNs attitude
towards their physical health care role [40]. It does not
evaluate knowledge so it has been adapted to include
20 physical health care multiple choice questions
[MCQ]. All MHNs in the study will be invited to
complete the adapted PHASe at baseline once rando-
mised and then again at the end of a year via a secure
website.
QRISK
®2 is a cardiovascular disease prediction algo-
rithm providing an individualised estimate of risk using
cholesterol, blood pressure and body mass index values,
medical history and taking account of the independent
contributions of ethnicity and social deprivation in the
UK (by post code). Data on the required variables will
be extracted from the HIP and the Patient Baseline
Demographics Form for all subjects in the HIP Pro-
gramme Group allowing an individual QRISK
®2t ob e
calculated. Face validity, good discrimination and cali-
bration of items has been established for QRISK
®2
[31,41].
Part 2: Process observation (objective 6)
A HIP Audit Form will capture details of recorded physi-
cal health needs, care plan interventions, goals, review
dates and any communication across the primary-second-
ary care interface (e.g. letters to and from GPs, practice
nurses) from the secondary (mental health) care patient
record. It will be administered in a standardised way by
the Trial Coordinator to the records of a purposeful sam-
ple of 36 HIP Programme Patient Participants. One to one
interviews (patients), focus groups (nurses) and telephone
interviews (psychiatrists and GPs) will be facilitated by the
Trial Coordinator using a series of open-ended questions
with the aim of:
￿ Obtaining insights into the patients’ and health
professionals’ experiences of using the HIP
￿ Considering which elements of the HIP Pro-
gramme were perceived as being most and least
helpful
￿ Exploring the participants’ perceptions of the effect
that they think the HIP Programme [as opposed to
TAU] has on them
￿ Uncovering any potential barriers and roadblocks
to using the HIP.
￿ E x p l o r i n gh o wt h eH I Pc o u l db er e f i n e da n d
enhanced.
Recruitment and randomisation
Registered MHNs working in a community mental health
setting can be included if they have been registered with
the Nursing and Midwifery Council [NMC] for at least 6
months, employed at Agenda for Change band 5-7, work
in one of the community mental health teams across the
two Trusts’ localities and have at least 5 patients on their
caseload with a primary diagnosis of SMI (as confirmed by
their Team Leader). Patients can be included if they are
aged over 18 years, on the caseload of the MHN partici-
pant at the start of the project and have a primary diagno-
sis of SMI (last recorded diagnosis in the patient record
either being schizophrenia, schizoaffective or bipolar dis-
order as confirmed by the Team Leader).
Following screening, MHNs will be excluded if they are
in their period of preceptorship, about to go on maternity
leave, are pregnant or up to 6 months post partum. Fol-
lowing screening, patients will be excluded if they cur-
rently lack the capacity to consent to treatment as
documented by a heath professional on Form 4 in their
case notes [42], have a serious or unstable medical condi-
tion (e.g. advanced/incurable cancer; severe co-morbidity
such as people on renal haemodialysis, end-stage COPD
or severe unpredictable pain), are pregnant or 6 months
post partum or where the Team Leader considers partici-
pation in the trial will put the patient, nurse or member
of the research team at increased risk or increased cost to
the service to manage risk.
Part 1
Clinical Community Team Leaders will be asked to
nominate MHNs who meet the inclusion criteria to the
Research Team who will then invite the MHN to parti-
cipate by letter. A member of the research team will
visit those nurses who respond positively to the invita-
tion, exchange information and take informed consent.
This will continue until a total of 50 MHNs have
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Page 4 of 11entered the trial. The importance of not sharing the HIP
tool or any training material will be explained to all
nurses participating in the trial.
Once the MHN is consented, their Team Leader will
be asked to list all patients with SMI on their caseload
and allocate them a number to maintain anonymity.
The Team Leader can justify exclusions in liaison with
the Trial Coordinator as necessary. Following random
selection of potential patients from this number list by
the University of East Anglia Clinical Research and
Trials Unit [CRTU], the Team Leader will break the
number code and ask nurse participants to hand a letter
of invitation and information pack to individual patients.
Additional copies of all information will be made avail-
able as required (e.g. for carers).
Part 2
This will start once the first 20 MHNs in the HIP
Group have completed Part 1 of the trial and include all
patients who remain in the study at one year:
1. UEA CRTU will randomly select a maximum of 2
patients each from each of the MHN study patients
until 36 patients are identified for the retrospective
case note audit.
2. The Process Observation Lead will select potential
subjects for the interviews and focus groups through
a process of purposeful sampling using screening
information. The Process Observation Lead will send
letters requesting an RSVP if able to attend an inter-
view/the focus group date and will purposefully
recruit to these groups until 10 patient interviews,10
places in the nurse focus groups per Trust site and
10 telephone interviews (for 5 psychiatrists and 5)
GPs are booked. Between 6 and 12 interviews are
recommended for qualitative interviews where there
is participant homogeneity [36].
Informed Consent
Written informed consent will be obtained prior to rando-
misation for all nurse participants, prior to baseline data
collection for all patient participants and prior to the start
of any interview or focus group for any patients or nurses
who choose to attend. Baseline data collection will take
place before the result of random allocation is revealed to
any individual participant. A signed consent form will be
requested by post from all doctors booking a telephone
interview. At each data collection point involving an inter-
view ongoing verbal consent will be sought and partici-
pants reminded of their right to withdraw. In addition
written information about the purpose of the PHASe
(adapted) will be available to read in a separate window
before the MHN decides if they wish to participate in the
online survey or not. MHNs participating in the online
survey will not be required to sign a specific consent form
as they can decide if they want to complete the survey or
not at each data collection stage. However, they will be
asked to indicate they have read and understood the study
information before they can submit their responses.
All written information will include contact informa-
tion (telephone numbers and email) for the project team
and the local office of the NHS Patient Advice and Lia-
sion Service [PALS] should any potential participants
want further information at any stage to support their
decision. Information will also be exchanged about the
availability of the same written information or further
information for carers, should they wish them to be
involved. A copy of the signed Informed Consent form
will be given to the participant. The original signed form
will be retained at the central Trial Office (University of
East Anglia). Where the participant is a patient, an addi-
tional copy will be filed in the case record and their GP,
Psychiatrist and Care-coordinator will be informed in
writing. Patient participants will also be reminded that
although data are anonymised, any disclosure which
potentially puts them or others at risk will be communi-
cated back to their MHN and Care Co-ordinator (if this
is a different person to the nurse). Similarly nurse partici-
pants will be reminded that any disclosure or evidence of
poor practice will be communicated back to their Team
Leader. In both cases the participant will be informed.
Randomisation
Part 1
All consented MHNs will be randomly assigned to either
the HIP or TAU arm of the trial. The randomisation sche-
dule will be designed, held and administered by the
CRTU. Once the Trial Coordinator receives a signed
informed consent form, the MHN will be allocated a
unique identification number. Once the MHN is rando-
mised no more patients from their caseload can be
included due to the need to complete all baseline mea-
sures before the training intervention takes place. The
MHN will be randomised once 5 patients have been
recruited from their caseload or after 6 weeks, whichever
occurs first. At this stage their number will be sent to the
CRTU by the Trial Coordinator, where allocation will be
by permuted blocks of random size. The Trial Coordinator
will be informed of the allocation and will directly contact
the MHN to inform them of their group allocation and
arrange for them to attend the HIP training if appropriate.
This will maintain blinding of the data collectors to group
allocation of participants.
All patients on the consented MHN subject’s caseload
meeting the inclusion criteria are eligible to participate.
Once a MHN has given their informed consent (but
before they are randomised) the Trial Coordinator will
ask the Clinical Team Leader to create a potential list of
patients from the caseload, allocating every patient on
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generate a list of 5 first choice and 5 reserve patient
n u m b e r sa tr a n d o ma n dl e t t e r sw i l lg oo u tt ot h e s e
patients via the Team Leader and Nurse Participant
inviting them to participate. Interested patients will be
asked to contact the research team to arrange a visit
from a researcher to enable the informed consent pro-
cess to be followed. This is to attempt to maintain
anonymity of the patient before they make a choice
about their interest in taking part and reduces any risk
of selection bias.
Part 2
The Process Observation Lead, will purposefully select
participants for the Process Observation after patients
have completed 12 months in the study using information
provided at baseline to achieve as representative a sample
as possible e.g. diagnosis, nursing grade, GP from small
practice or large health centre, urban or city region. 36
patients from the HIP Programme group will be purpose-
fully selected for the HIP Audit. A letter of invitation to
the interview or focus group, information sheets and
response slips will be sent in the post with a follow up
information exchange and informed consent visit from the
Trial Coordinator once a positive response is received
until 10 participants are identified for each group or set of
interviews. Psychiatrists and GPs will not be visited but
information exchanged and consent will be checked at the
start of the telephone interview.
Baseline and follow up assessments
Assessments will be completed by a researcher and take
place at baseline and 52 weeks post-randomisation.
Demographic information will be collected at baseline e.
g. grade, caseload size, year of qualification, previous
physical health care education (MHNs) and diagnosis,
age, post-code (patients). The following validated mea-
sures will be used at baseline and 52 weeks in both the
HIP and TAU groups:
1. PCS and MCS of the SF36v2
2. EQ-5D
3. HRU (patient)
4. PHASe adapted
The following will be used at baseline and at 52 weeks
in the HIP programme group only:
1. HRU: Health Service Use Questionnaire (nurse)
2. The QRISK
®2
and in a sample of patients from the HIP Programme
group after 12 months
1. HIP Audit Form
Feedback will be sought from a sample of HIP Pro-
gramme group participants in the Patient Interviews,
Nurse Focus Groups and Psychiatrist/GP telephone
interviews after one year using the Patient Semi-struc-
tured Interview Schedule, the Nurse Focus Group Inter-
view Schedule and the Psychiatrist/GP Telephone
Interview Schedule.
Description and core principles of the intervention
The HIP is a gender specific 27-item physical health risk
assessment tool. The profile includes items on cardio-
vascular risk factors such as BMI (body mass index), cho-
lesterol, diet, smoking and exercise but also addresses
other aspects of wellbeing such as sexual health and satis-
faction, sleep, dental and eye health and breast, prostate
and testicular self examination. Each of the 27 items
are flagged either green (healthy) or red (not healthy). The
HIP then directs nurses to evidence/guideline-based inter-
ventions for each of the red flagged items [43].
HIP training takes place in a 6 hour workshop deliv-
ered by JW, RG or MJ and will include: how to use the
HIP; how to engage patients in health behaviour change
and work with them to develop a patient specific health
action plan. A HIP Manual will be provided. Compe-
tency in physical observation skills are expected of all
MHNs employed in the NHS, assured through a conti-
nuing professional development process which will be
signposted in the training, the HIP Manual and by the
Team Leaders through the usual clinical supervision
processes, if necessary.
Definition of End of Study
Part 1
Date of the last 52-week visit for the last patient.
Part 2
Date of the last interview/focus group or date of the last
patient HIP Audit visit, whichever occurs last.
Analysis
Description of Statistical Methods
The analysis and reporting of the trial will be undertaken
in accordance with Consolidated Standards of Reporting
Trials [CONSORT] [44,45]. Standard methods will be
used to provide tabular and graphical summaries as
appropriate for continuous and categorical variables. Pri-
mary and secondary outcomes will be compared between
intervention and control groups using linear or logistic
regression as appropriate including a random term to
allow for nurse clusters. Further adjusted estimates will
be calculated by including the baseline value of the out-
come in these models. Where between group differences
are observed in demographics or patient characteristics
at baseline, terms representing these variables will also be
included to obtain adjusted estimates of the intervention
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between groups. If differences occur these may be incor-
porated into a multilevel model structure. The latest
available versions of the Statistical Package for the Social
Sciences [SPSS] and Stata will be used for the analysis. It
is not our intention to conduct any subgroup analyses.
Baseline analyses
To assess external generalisability, demographic and
clinical characteristics of patient participants invited to
participate in the study at baseline will be compared
with participants who are subsequently randomised and
participants who are screened but not randomised. The
specific criteria by which participants are excluded from
randomisation will be tabulated. Baseline comparability
will be assessed using descriptive statistics only.
Number of Participants
Part 1
A sample size of 50 MHNs will be sought (25 in the
HIP and 25 in the TAU group), with 5 patients each
resulting in an overall sample size of 250 patients (125
in the HIP and 125 in the TAU group). Based on a stan-
dard deviation of about 12 points as found in MOS
patients (adults in various settings with SMI in the US),
a difference in means between intervention and TAU of
6p o i n t si nt h eS F 3 6 v 2P C Ss u b s c a l ei se q u i v a l e n tt oa
medium effect size. The proposed sample size gives a
power of 86% to detect this if an intraclass correlation
of 0.1 is assumed and nearly 80% if an intraclass correla-
tion of 0.2 is assumed using a 2-sided significance level
of 0.05 and allowing for an estimated 20% attrition rate
i.e. 1 patient per nurse.
All MHNs in the HIP and TAU groups will be invited
to participate in the online PHASe adapted at baseline
and one year. Response rates will be reported. All
patients remaining the HIP Group at one year will pro-
vide data for evaluation of any change in their QRISK
®2
Scores. Retention rates will be reported.
Part 2
The patient records of the 36 randomly selected
patients from the HIP Programme Group will be
audited using the HIP Audit Form. We will purpose-
fully recruit from the HIP Group (on completion of
Part 1) 10 patients to participate in the Patient Semi-
structured Interviews, 10 nurses to participate in a
Focus Group (per Trust study site) 5 psychiatrists and
5 GPs to participate in the telephone interviews. (30 in
total). The aim of this element of the project is to eli-
cit general feedback that will help in refining and
further developing the HIP. The qualitative literature
indicates that this number of data collection interviews
per homogenous professional or patient group should
allow us to reach saturation of themes [46].
Feasibility of target sample size
Localities in the two NHS sites provide services via
community mental health, assertive outreach and recov-
ery teams. Across the two NHS Trusts there are a total
of 16 localities and 33 teams. We will invite every band
5-7 MHN in these teams to participate and once
recruited, screen every patient on their caseload for the
inclusion criteria before inviting randomly selected
patients to take part as a patient subject in the rando-
mised trial. To make this achievable we will work closely
with Clinical Team Leaders. Our planned recruitment
rate is 25 patients per month (excluding August and
December).
Efficacy analysis
Efficacy of the intervention will be assessed by compar-
ing the patient outcomes at 52 weeks between the two
groups allowing for the clustering effect of the nurse.
Further, adjusted estimates will be obtained by identify-
ing baseline variables that differ between the two
groups, which are related to the outcome and incorpor-
ating these into the analyses.
Inclusion in Analysis
An intention to treat (ITT) analysis will be performed. The
ITT analysis set will comprise all patients who were ran-
domised to a group at baseline (HIP Programme or TAU
group), irrespective of any change to the other group over
t h ec o u r s eo ft h et r i a l .T h i si st h em a i na n a l y s i sa n dw i l l
be used for evaluation of all endpoints. However, we
acknowledge there may be attrition due to nurses leaving
teams and where patients may be unavoidably switched to
a nurse participant caseload in a group other than the one
they were randomised to at baseline or to a MHN not in
the study. To enable an evaluation of the effects of this on
the primary outcome we will undertake and report a sec-
ondary per protocol [PP] analysis. HIP and non-HIP
patients will be included in groups on an intention to treat
basis. The primary analysis will include non-missing data
only. However, where there is attrition at follow up the
baseline characteristics of missing and non-missing values
will be compared. Further, we will perform sensitivity ana-
lyses by (i) assuming zero change in scores and (ii)
employing current multiple imputation techniques.
A per protocol analysis will also be performed. Per
protocol will be defined as the participant remaining in
the same arm of the study as at randomisation.
Economic Analysis
This will assess whether HIP represents a cost-effective
use of scarce NHS resources when compared to TAU. In
line with guidance by NICE [47], costs will be calculated
from the perspective of the NHS and personal social ser-
vices and encompass those costs that are potentially
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tor the levels of resource use associated with completing
the HIP (including those associated with any associated
tests/investigations that are recommended, changes in
medication use and any other service referrals). For
patients in both arms we will also monitor visits to other
health care professionals, any admissions to hospital, and
medication usage. Appropriate unit costs will subsequently
be assigned to each of these items e.g. [46].
The measures of effectiveness employed in the eco-
nomic analysis will be the 5 dimensions of the EQ-5D
[48], used to calculate quality-adjusted-life-years
(QALYs) associated with both the intervention and
TAU.
An economic model will be constructed to estimate
both the mean overall cost and mean overall effect asso-
ciated with both the intervention and treatment as usual.
If one of these options were shown to be less costly and
more effective than the other then this would suggest
that it ‘dominates’ the other, and represents a cost-effec-
tive use of scarce resources. Alternatively, the incremen-
tal cost-effectiveness ratio associated with the HIP will be
estimated and assessed in relation to a set of cost-effec-
tiveness thresholds e.g. a threshold of £20,000-£30,000
per QALY is recommended by NICE [47]. The associated
level of uncertainty will also be characterised e.g. by esti-
mating the cost-effectiveness acceptability curve [CEAC]
for each intervention [49]. Additionally, sensitivity analy-
sis will be undertaken to assess the robustness of conclu-
sions to key assumptions.
Cardiovascular risk
95% confidence intervals will be calculated for change in
QRISK
©2 for the HIP group participants.
Process observation
Data from the HIP Audit Forms will be analysed using
SPSS. Patient semi-structured interviews will be
recorded by taking notes in the interview and seeking
feedback from the patient participant that the notes
accurately reflect what was said. The nurse focus groups
and doctors’ telephone interviews will be audio-recorded
and transcribed verbatim. Transcripts from all inter-
views and focus groups will be coded using thematic
analysis [50]. The results will then be returned to the
participants for member checking [51].
Potential Bias
T h es u b j e c t i v en a t u r eo ft h eself-report instruments,
used for assessment, is accepted and every effort will be
made to minimise potential bias which may occur due
to this dynamic. In particular, patients may over or
under report their health status depending on the trial
arm to which they have been assigned. We acknowledge
there may be attrition so to enable an evaluation of the
effects of this on the primary outcome we will undertake
a secondary per protocol[PP] analysis to compare with
the ITT.
Discussion
Physical comorbidities are common in people with SMI
and have a profound effect on both quality and length of
life. Poor physical health compounds the already major
issue of social exclusion in this population. Preventing,
recognising and treating physical comorbidity is central
to holistic care and this is reflected in standards and
guidelines from the Department of Health, the Nursing
and Midwifery Council and the National Institute of
Health and Clinical Excellence. Despite recent policy dri-
vers to improve screening and intervention, concerns
remain about the confidence and competence of the
existing workforce to address this problem. Two studies,
five years apart, highlighting this deficit in the MHN
workforce in the UK have used observational designs in
small convenience samples [26,52].
To date the only published experimental studies of
implementation of a package of interventions to improve
physical health in SMI have included a number of service
evaluations and one RCT that aimed to improve screening
rates [32,53-55]. With the exception of the HIP case series
evaluation [32], these studies introduced new staff in a
physical health role as an adjunct to the usual care deliv-
ered by the mental health team for the duration of a speci-
fic pilot project [53-55]. There remains a need to find a
cost-effective evidence-based solution that avoids expen-
sive and lengthy retraining or restructuring of services and
roles and enables physical health screening and interven-
tion on a population level.
In designing the HIP Programme, our focus has been to
enable any MHN in contact with the person with SMI, to
exploit the opportunity to monitor physical health and
offer appropriate evidence-based or recommended inter-
vention through their usual contact and role, rather than
as an adjunct service. This is a pragmatic approach to the
problem, yet it remains complex in terms of its evaluation
and dissemination. Complex interventions contain several
interacting components [56]. The HIP Programme targets
the MHN, the patient and the organisation and requires
them all to interact. For example, a MHN using the HIP
with a patient will need to find time within their existing
role to engage the patient in the HIP process and commu-
nicate within their own organisation and across the pri-
mary-secondary care interface to enable additional
screening or access to intervention for the patient.
The Medical Research Council recommend researchers
pay attention to the interplay between development, fea-
sibility, evaluation and implementation when designing
complex health interventions [56]. In the development
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health nurses, patients, psychiatrists and GPs reporting
that it is acceptable, avoids duplication of work, enables
previously unidentified physical comorbidities to be
uncovered and improves care planning and interface
communication. Clinical utility and acceptability were
then established in an exploratory case series within a
community MH service in Scotland [32].
To maximise success in the future implementation of
the HIP we have included an education package to meet
the individual and organisational needs of the staff most
likely to be in contact with people with SMI. The cluster
design with the MHN as the cluster has been adopted
because the focus of the intervention depends on the
training and adoption of the HIP by MHNs. In evaluating
the success of our intervention, the HIP and the training
package together [the HIP Programme], we will evaluate
patient outcomes and conduct a process observation. This
will allow us to report education outcomes (any change in
nurse knowledge of and attitudes towards a physical
healthcare role using the adapted PHASe [40]) in addition
to our primary evaluation of effectiveness and cost
effectiveness.
The primary end point of this proposed study, change in
physical related quality of life, has meaning to patients,
carers, practitioners and policy makers and will formally
explore the clinical potential of the tool. We have a speci-
fic qualitative element to explore patient, practitioner and
medical experience of the HIP. Qualitative and audit data
will enable us to more fully test the acceptability of this
approach and further refine it as necessary. The health
economic element of the study will provide important
information about the costs of disseminating this approach
across the NHS in terms of any additional service costs
and Quality Adjusted Life Years (QALYs). The evaluation
of HIP trainees knowledge and attitude towards physical
health post HIP training will inform future workforce
training and implementation plans.
If successful, this study will demonstrate the clinical and
economic potential of an innovative brief training package
and pragmatic clinical profile (the HIP Programme) that
makes use of and builds upon the existing skills of MHNs
who have the most contact with these patients and who
already coordinate care and treatment between services.
MHNs working in the community will be trained to pro-
file and plan care around individual physical health issues
in a real world setting. If successful, the quality of our evi-
dence will inform regional dissemination and a future defi-
nitive effectiveness study to enable policy makers to
recommend the HIP Programme across the NHS.
Current Study Status
NHS ethics approval was granted in December 2010 and
Research and Development Approval from the sponsor
NHS Trust site in March 2011. Active recruitment com-
menced on 04 April 2011.
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